Advertisement

Compassionate use of unauthorized drugs: Legal regulations and ethical challenges

  • Jan Borysowski
    Correspondence
    Corresponding author.
    Affiliations
    Centre for Studies on Research Integrity, Institute of Law Studies, Polish Academy of Sciences, Nowy Świat 72, 00-330 Warsaw, Poland

    Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka Str. 59, 02-006 Warsaw, Poland
    Search for articles by this author
  • Andrzej Górski
    Affiliations
    Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka Str. 59, 02-006 Warsaw, Poland

    Laboratory of Bacteriophages, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla Str. 12, 53-114 Wrocław, Poland
    Search for articles by this author
Published:April 26, 2019DOI:https://doi.org/10.1016/j.ejim.2019.04.008

      Highlights

      • Compassionate use is use of unauthorized drugs outside of clinical trials.
      • Many countries have introduced legal regulations concerning compassionate use.
      • Compassionate use is associated with a number of ethical challenges.
      • Ethical review of compassionate use is quite controversial.
      • Some ethics codes contain guidelines regarding compassionate use.

      Abstract

      Compassionate use (also referred to as expanded access) is therapeutic use of unauthorized drugs outside of clinical trials. The objective of this review is to discuss practical aspects of the current legal regulations concerning compassionate use that have been introduced in the European Union, the USA (both the Food and Drug Administration regulations and Right-to-try laws), Canada and Australia. We also present main ethical challenges associated with use of unauthorized drugs such as possible difficulties with obtaining informed consent and fair patient selection. Moreover, we discuss guidelines, especially those contained in the Declaration of Helsinki, which may aid doctors in the ethical conduct of compassionate treatments.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Caplan A.L.
        • Bateman-House A.
        Should patients in need be given access to experimental drugs?.
        Expert Opin Pharmacother. 2015; 16: 1275-1279
        • European Medicines Agency (Committee for Medicinal Products for Human Use)
        Guideline on compassionate use of medicinal products, pursuant to article 83 of regulation (EC) no 726/2004.
        (Available at)
        • Borysowski J.
        • Ehni H.J.
        • Górski A.
        Ethics review in compassionate use.
        BMC Med. 2017; 15136https://doi.org/10.1186/s12916-017-0910-9
        • Darrow J.J.
        • Sarpatwari A.
        • Avorn J.
        • Kesselheim A.S.
        Practical, legal, and ethical issues in expanded access to investigational drugs.
        N Engl J Med. 2015; 372: 279-286
        • Caplan A.L.
        • Teagarden J.R.
        • Kearns L.
        • Bateman-House A.S.
        • Mitchell E.
        • Arawi T.
        • et al.
        Fair, just and compassionate: a pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
        J Med Ethics. 2018; 44: 761-767
        • Cappuzzo F.
        • Soo R.
        • Hochmair M.
        • Schuler M.
        • Lam K.C.
        • Stehle G.
        • et al.
        Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
        Future Oncol. 2018; 14: 1477-1486
        • Plourde P.V.
        • Jeha S.
        • Hijiya N.
        • Keller F.G.
        • Silverman L.B.
        • Rheingold S.R.
        • et al.
        Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
        Pediatr Blood Cancer. 2014; 61: 1232-1238
        • Jarow J.P.
        • Lemery S.
        • Bugin K.
        • Khozin S.
        • Moscicki R.
        Expanded access of investigational drugs: the experience of the center of drug evaluation and research over a 10-year period.
        Ther Innov Regul Sci. 2016; 50: 705-709
      1. Regulation (EC) no 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.
        • Balasubramanian G.
        • Morampudi S.
        • Chhabra P.
        • Gowda A.
        • Zomorodi B.
        An overview of compassionate use programs in the European Union member states.
        Intractable Rare Dis Res. 2016; 5: 244-254
      2. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use.
        • Electronic Code of Federal Regulations
        Expanded access to investigational drugs for treatment use.
      3. Electronic code of Federal Regulations. Treatment use of an investigational device.
        • Lynch H.F.
        • Zettler P.J.
        • Sarpatwari A.
        Promoting patient interests in implementing the Federal Right to try act.
        JAMA. 2018; 320: 869-870
        • Gabay M.
        RxLegal: a rapid review of right-to-try.
        Hosp Pharm. 2018 Jul; 53: 234-235
        • Joffe S.
        • Lynch H.F.
        Federal Right-to-try Legislation – threatening the FDA's public health Mission.
        N Engl J Med. 2018; 378: 695-697
      4. Health Canada. Guidance document for industry and practitioners – special access programme for drugs. 2013. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs/guidance-industry-practitioners-special-access-programme-drugs-health-canada-2008.html Accessed 2018-16-07.

      5. Therapeutic Goods Administration. Authorised prescribers. 2017. Available at: https://www.tga.gov.au/form/authorised-prescribers Accessed 2018-16-07.

      6. Therapeutic Goods Administration. Special access scheme. 2018. Available at: https://www.tga.gov.au/form/special-access-scheme Accessed 2018-16-07.

        • DiMasi J.A.
        • Grabowski H.G.
        • Hansen R.W.
        Innovation in the pharmaceutical industry: new estimates of R&D costs.
        J Health Econ. 2016; 47: 20-33
        • Hwang T.J.
        • Carpenter D.
        • Lauffenburger J.C.
        • Wang B.
        • Franklin J.M.
        • Kesselheim A.S.
        Failure of investigational drugs in late-stage clinical development and publication of trial results.
        JAMA Intern Med. 2016; 176: 1826-1833
        • Raus K.
        An analysis of common ethical justifications for compassionate use programs for experimental drugs.
        BMC Med Ethics. 2016; 17: 60
        • De Panfilis L.
        • Satolli R.
        • Costantini M.
        Compassionate use programs in Italy: ethical guidelines.
        BMC Med Ethics. 2018; 19: 22https://doi.org/10.1186/s12910-018-0263-8
        • Caplan A.L.
        • Bateman-House A.
        • Waldstreicher J.
        Compassionate use: a modest proposal.
        Am Soc Clin Oncol Educ Book. 2016; 35: e2-e4https://doi.org/10.14694/EDBK_156130
        • Puthumana J.
        • Miller J.E.
        • Kim J.
        • Ross J.S.
        Availability of investigational medicines through the US Food and Drug Administration's expanded access and compassionate use programs.
        JAMA Netw Open. 2018; 1e180283https://doi.org/10.1001/jamanetworkopen.2018.0283
        • Walker M.J.
        • Rogers W.A.
        • Entwistle V.
        Ethical justifications for access to unapproved medical interventions: an argument for (limited) patient obligations.
        Am J Bioeth. 2014; 14: 3-15
        • Nardini C.
        The ethics of clinical trials.
        Ecancermedicalscience. 2014; 8: 387
        • Lorigan P.
        • Ascierto P.A.
        • Dummer R.
        • Eggermont A.M.
        • Flaherty K.T.
        • Garbe C.
        • et al.
        Expanded access programmes: patient interests versus clinical trial integrity.
        Lancet Oncol. 2015; 16: 15-17https://doi.org/10.1016/S1470-2045(14)71161-1
        • Folkers K.M.
        • Bateman-House A.
        Improving expanded access in the United States: the role of the institutional review board.
        Ther Innov Regul Sci. 2018; 52: 285-293
        • Hajibabaee F.
        • Joolaee S.
        • Cheraghi M.A.
        • Salari P.
        • Rodney P.
        Hospital/clinical ethics committees' notion: an overview.
        J Med Ethics Hist Med. 2016; 9: 17
        • Brierley J.
        • Larcher V.
        Compassionate and innovative treatments in children: a proposal for an ethical framework.
        Arch Dis Child. 2009; 94: 651-654
        • Borysowski J.
        • Ehni H.J.
        • Górski A.
        Ethics codes and use of new and innovative drugs.
        Br J Clin Pharmacol. 2019; 85: 501-507
        • World Medical Association
        Declaration of Helsinki.
        • Asplund K.
        • Hermerén G.
        The need to revise the Helsinki declaration.
        Lancet. 2017; 389: 1190-1191